Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability

Journal of Cardiology

Volumn 58, Issue 2, 2011, Pages 151-157

  Soeki, Takeshi ^a   Niki, Toshiyuki ^a   Kusunose, Kenya ^a   Bando, Sachiko ^a   Hirata, Yoichiro ^a   Tomita, Noriko ^a   Yamaguchi, Koji ^a   Koshiba, Kunihiko ^a   Yagi, Shusuke ^a   Taketani, Yoshio ^a   Iwase, Takashi ^a   Yamada, Hirotsugu ^a   Wakatsuki, Tetsuzo ^a   Akaike, Masashi ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiotensin receptor blocker; Atherosclerosis; Coronary plaque; Inflammation; Pentraxin 3

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR2; PENTRAXIN 3; TELMISARTAN;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY SINUS BLOOD FLOW; DENSITY GRADIENT; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; MORNING DOSAGE; PERIPHERAL CIRCULATION; PROTEIN EXPRESSION;

AGED; ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; CORONARY SINUS; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 80052027372     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.04.005     Document Type: Article

References (21)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
3. Blake G. Novel markers of vascular wall inflammation. Circ Res 2001, 89:763-771.
4. Zakynthinos E., Pappa N. Inflammatory biomarkers in coronary artery disease. J Cardiol 2009, 53:317-333.
5. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
6. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366.
7. Cianchetti S., Del Fiorentino A., Colognato R., Di Stefano R., Franzoni F., Pedrinelli R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008, 198:22-28.
8. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606.
9. Inoue K., Sugiyama A., Reid P.C., Ito Y., Miyauchi K., Mukai S., Sagara M., Miyamoto K., Satoh H., Kohno I., Kurata T., Ota H., Mantovani A., Hamakubo T., Daida H., et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007, 27:161-167.
10. Tsujikawa T., Nomura M., Nakayasu K., Kawano T., Nakaya Y., Ito S., Nishitani H. Risk factors associated with soft coronary artery plaques in Japanese, as determined by 16 slice multidetector-row computed tomography. J Med Invest 2006, 53:310-316.
11. Rolph M.S., Zimmer S., Bottazzi B., Garlanda C., Mantovani A., Hansson G.K. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002, 22:10-14.
12. Savchenko A., Imamura M., Ohashi R., Jiang S., Kawasaki T., Hasegawa G., Emura I., Iwanari H., Sagara M., Tanaka T., Hamakubo T., Kodama T., Naito M. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008, 215:48-55.
13. Peri G., Introna M., Corradi D., Iacuitti G., Signorini S., Avanzini F., Pizzetti F., Maggioni A.P., Moccetti T., Metra M., Cas L.D., Ghezzi P., Sipe J.D., Re G., Olivetti G., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
14. Schroeder S., Kopp A.F., Baumbach A., Meisner C., Kuettner A., Georg C., Ohnesorge B., Herdeg C., Claussen C.D., Karsch K.R. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 2001, 37:1430-1435.
15. Inoue F., Sato Y., Matsumoto N., Tani S., Uchiyama T. Evaluation of plaque texture by means of multislice computed tomography in patients with acute coronary syndrome and stable angina. Circ J 2004, 68:840-844.
16. Ballantyne C.M., Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005, 6:21-29.
17. Mazzone A., De Servi S., Mazzucchelli I., Bossi I., Ottini E., Vezzoli M., Meloni F., Lotzinker M., Mariani G. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart 2001, 85:571-575.
18. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.
19. Fliser D., Buchholz K., Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004, 110:1103-1107. EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators.
20. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
21. Ono Y., Nakaya Y., Bando S., Soeki T., Ito S., Sata M. Telmisartan decreases plasma levels of asymmetrical dimethyl-l-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 2009, 50:73-83.